GEN Exclusives

More »

GEN News Highlights

More »
Jun 28, 2010

Four Phase III Trials Confirm Benefits of BI’s Oral, Once-Daily Type 2 Diabetes Therapy

  • Treating type 2 diabetes patients using Boehringer Ingelheim’s (BI) oral candidate, linagliptin, leads to statistically significant and sustained reductions in blood sugar levels, according to data from four Phase III trials. The international placebo-controlled studies showed that when used as monotherapy or in combination with either metformin, pioglitazone, or metformin plus a sulfonylurea, treatment using linagliptin led to significant reductions in blood levels of hemoglobin A1c (HbA1c), fasting plasma glucose and postprandial glucose. The Phase III trial data was presented at the recent American Diabetes Association Scientific Sessions in Orlando.

    Treatment using the once-daily oral drug candidate also led to improvements in beta cell function, the decline in which is believed to represent a key factor in the progression of type 2 diabetes, BI states. Additional data from the trials showed that in patients with mild and moderate renal impairment, linagliptin blood plasma levels were comparable to those in type 2 diabetes patients with normal renal function. BI says this finding is consistent with data suggesting linagliptin may have a primarily nonrenal route of excretion.

    Linagliptin is a once-daily oral dipeptidyl peptidase-4 inhibitor designed to target the incretin hormones GLP-1 and GIP. The drug candidate is the most advanced in BI’s diabetes pipeline. The global clinical program for linagliptin includes studies of up to two years and trials in type 2 diabetes patients with renal impairment. The firm is separately developing a sodium-glucose cotransporter inhibitor candidate BI-10773, which is designed to block tubular reabsorption of glucose in the kidney. BI says Phase II trials with BI-10773 have now been concluded.

    More upstream in the firm’s diabetes pipeline is an 11β-HSD1 inhibitor, which is believed to work by lowering intracellular cortisol concentrations and helping to prevent cortisol-related detriments in terms of insulin sensitivity, blood lipid levels, and vascular function.

     


Readers' Comments

Posted 03/18/2013 by Subhash Chandra

Head to head comparison of different DPP-4 INHIBITORS WILL BE IN ORDER TO OPT FOR A PARTICULAR agent

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?